Notably, combined EGFR and TNF-α inhibition significantly reduces viability of TMZ-resistant (MGMT unmethylated) recurrent human GBM cells, and is as potent as TMZ in MGMT methylated cells [393]. This evidence concerns the gene MGMT and glioblastoma.